CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
Articles > Article · 2021
Authors: Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian, Cigir Biray Avcı
Advanced Pharmaceutical Bulletin, International, Scopus, 2021, vol 12, pp 476-489
Summary
Immunotherapy has become a prominent strategy for the treatment of cancer. A method that improves the immune system's ability to attack a tumor (Enhances antigen binding). Targeted killing of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising immunotherapy technique in the treatment of cancers. For this purpose, the patient's immune cells, with genetic engineering aid, are loaded with chimeric receptors that have particular antigen binding and activate cytotoxic T lymphocytes. That increases the effectiveness of immune cells and destroying cancer cells. This review discusses the basic structure and function of CAR-T cells and how antigenic targets are identified to treat different cancers and address the disadvantages of this treatment for cancer.